Determine the necessary mass, volume, or concentration for preparing a solution.
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at 2-8°C Ships Wet ice Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
MIF098 is a macrophage migration inhibitory factor ( MIF ) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.
In Vitro
MIF098 (0-10 μM, 48 h) inhibits mPASMC cell proliferation and migration in a concentration-dependent manner, by blocking the migration inhibitory factor (MIF) pathway. MIF098 reduces collagen synthesis and pulmonary artery fibrosis by inhibiting the TGFβ1/Smad2/3 pathway. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Mouse pulmonary artery smooth muscle cells (mPASMCs) Concentration: 0-10 μM Incubation Time: 48 hours Result: Reduced expression of cell cycle related proteins such as cyclin D1, CDK4 and CDK6 in PDGF-BB and increased expression of cell-cycle arrest proteins such as P53 and P21. Reduced TGFβ1-induced fibronectin (FN), collagen I (col I), and collagen II (col II) expression and phosphorylation of Smad2 and Smad3.
In Vivo
MIF098 (intraperitoneal injection, 40 mg/kg, once a day, 4 weeks) attenuates the process of hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Hypoxic male C57BL/6J mice Dosage: 40 mg/kg Administration: Intraperitoneal injection; once a day; 4 weeks Result: Reduced right ventricular systolic pressure (RVSP), percentage medial wall thickness, muscularization and right ventricle collagen deposition. Decreased percentage of collagen fibers in pulmonary artery (PA).
Form:Solid
| Peso molecular | 255.27 |
|---|
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubilidad | DMSO : 180 mg/mL (705.14 mM; ultrasonic and warming and heat to 60°C) |
|---|